• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Johnson & Johnson (NY: JNJ )

    162.78 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Sep 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open -
    Bid (Size) 162.60 (10)
    Ask (Size) 163.50 (1)
    Prev. Close 162.78
    Today's Range 162.78 - 162.78
    52wk Range 143.13 - 168.85
    Shares Outstanding 2,628,679,824
    Dividend Yield 2.92%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Why NYSE:JNJ provides a good dividend, while having solid fundamentals.
    Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
    Via Chartmill

    Performance

    YTD
    +1.76%
    +1.76%
    1 Month
    -1.11%
    -1.11%
    3 Month
    +10.59%
    +10.59%
    6 Month
    +4.50%
    +4.50%
    1 Year
    +1.57%
    +1.57%

    More News

    Read More
    Is Johnson & Johnson Stock a Buy?
    Via The Motley Fool
    Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
    From Beasley Allen Law Firm
    Via Business Wire
    Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
    From Johnson & Johnson
    Via Business Wire
    The Latest Analyst Ratings For Johnson & Johnson
    Via Benzinga
    Unpacking the Latest Options Trading Trends in Johnson & Johnson
    Via Benzinga
    Competitor Analysis: Evaluating Johnson & Johnson And Competitors In Pharmaceuticals Industry
    Via Benzinga
    Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
    Via Benzinga
    Exposures Product Safety
    Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
    Via Benzinga
    Exposures Product Safety
    2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
    Via Investor's Business Daily
    2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement
    Via The Motley Fool
    Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug
    Via Benzinga
    Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
    Via MarketBeat
    Topics Economy
    Exposures Economy Interest Rates
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Via Talk Markets
    Topics ETFs
    Should You Buy Novavax Stock After This Regulatory Win?
    Via The Motley Fool
    How To Earn $500 A Month From Johnson & Johnson Stock
    Via Benzinga
    Metals in Tampons: FDA Initiates New Safety Measures and Testing
    Via Benzinga
    Exposures Product Safety
    Sony Music-Universal Music JV Hits Johnson & Johnson With Copyright Lawsuit Over Unlicensed Music Use Covering 80 Videos
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Johnson & Johnson's Mid-Stage Lung Cancer Trial Reveals Fewer Infusion-Related Reactions
    Via Benzinga
    3 Safe Stocks with Safe Dividends for Your Portfolio
    Via MarketBeat
    Topics Economy
    Exposures Economy
    Is Hims & Hers Health the Next Teladoc?
    Via The Motley Fool
    Exposures COVID-19
    2 Stocks That Are Passive Income Machines to Buy and Hold Forever
    Via The Motley Fool
    Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
    Via Benzinga
    Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.